Private Markets – Tridek-One raises €16 million to develop first-class anti-checkpoint immunotherapies

Tridek-One also welcomes Laurence de Schoulepnikoff as CEO and Erik van den Berg as President.

Tridek-One SAS, a biotechnology start-up specializing in the research and development of CD31 agonists to restore immune balance, today announces that it has raised €16 million in a funding round led by Swiss Pureos BioVentures. This operation is being carried out alongside newcomers Bpifrance, through its InnoBio2 fund, and Bioqube Ventures (Belgium), with the participation of historical investors partners AdBio and Advent Life Sciences. The funds will be used primarily to identify drug candidates to be developed against autoimmune diseases, conduct regulatory pre-clinical studies and structure the company. In 2019, Tridek-One raised €3 million during a first round of funding with partners AdBio (France) and Advent Life Sciences (UK).

Founded in 2018 by Dr Giuseppina Caligiuri and Pr Antonino Nicoletti, researchers at the INSERM 1148 unit (Paris), with the support of AdBio partners as a historic investor, Tridek-One is developing a CD31 agonist approach aimed at modulating immune activation for the treatment of autoimmune diseases.

Tridek-One has also appointed Laurence de Schoulepnikoff as CEO effective July 1, 2022. An expert in the pharmaceutical and biotechnology industry, Laurence de Schoulepnikoff has extensive experience in transactions and R&D activities in the life sciences area. She has worked for biotechnology start-ups funded by venture capital firms and for medium-sized private companies as well as multinationals. Prior to joining Tridek-One, she was Director of Business Development and Director of Operations at AMAL Therapeutics, a Swiss biotechnology company specializing in therapeutic cancer vaccines. AMAL was acquired in 2019 by Boehringer Ingelheim. At Tridek-One, Ms. de Schoulepnikoff will be responsible for strategy and development, as well as consolidating the company’s structure.

“I am delighted to join Tridek-One and grateful for this opportunity to lead the company as we enter a strategic period where we look forward to reaching several important pre-clinical milestones and building a leading biotechnology for the treatment of autoimmune diseases »says Laurence de Schoulepnikoff, CEO of Tridek-One.

Following this funding round, Klaus Breiner of Pureos Bioventures and Benoit Barteau of Bpifrance join the company’s board of directors, as does Erik van den Berg, CEO of AM-Pharma, who becomes its independent chairman.

“I am delighted to join Tridek-One as President as the company is strengthened with an experienced team and the support of a syndicate of international investors who have chosen to rely on decades of research conducted by the team of Dr Giuseppina Caligiuri and Pr Antonino Nicoletti »adds Erik van den Berg.

“There is still a significant unmet medical need in many autoimmune diseases. The agonist approach of inhibitory immune system receptors such as CD31 could rebalance the immune system without a systemic immunosuppressive effect. We are delighted to develop this concept with Tridek-One and support them in their research and pre-clinical stages.”explains Klaus Breiner, associate director of Pureos Bioventures.

“AdBio partners were one of the founding investors of Tridek-One in 2018, so Advent Life Sciences joined us. We are pleased to welcome new investors who strongly believe in Tridek-One’s disruptive innovation. This confirms our initial choice as an entrepreneur-investor”says Alain Huriez, president of AdBio partners.

“Being supported by investors who believe in the Tridek-One project is a fantastic opportunity. This will allow us to accelerate our work to identify and develop first-class immune checkpoint agonists capable of controlling serious inflammatory diseases.”conclude Dr. Giuseppina Caligiuri and Pr Antonino Nicoletti, scientific founders of Tridek-One.

Leave a Comment